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Previewsunlikely given the authors were able to
obtain EpiSCs from blastocysts that
were exposed to a LIF-Jak inhibitor
throughout the derivation process. They
were also able to obtain EpiSCs from
NOD blastocysts in conditions that never
produce ESCs.
Direct reprogramming of somatic cells
to an EpiSC state was recently described
(Han et al., 2011). In this paper, the
authors elegantly demonstrated that the
process did not go through an ESC inter-
mediate by starting with female somatic
cells from a mouse with an X-linked GFP
transgene. With this model, the GFP-
negative population targeted by Han
et al. all carried the GFP transgene on
the inactive X chromosome, and the
resulting reprogrammed EpiSCs all re-
mained GFP-negative. If the reprogram-
ming process had transitioned through
an ESC intermediate, X chromosome re-
activation would have resulted in about
50% GFP-positive cells (Han et al.,
2011). This work illustrated that a primed242 Cell Stem Cell 8, March 4, 2011 ª2011 Epluripotent state can be achieved without
transiting through a naive one.
It is welcome news that mouse, human,
and other mammalian blastocyts are all
primed to produce pluripotent cell lines
with similar characteristics. Although
they do not necessarily exhibit naive
traits, such as maintenance of two active
X chromosomes, they are clearly pluripo-
tent, given that they are able to generate
teratomas with cells from all three clas-
sical germ layers (Najm et al., 2011).
EpiSCs, and their ability to differentiate
in vitro, will prove to be indispensable for
understanding early developmental
events, especially around gastrulation.
Furthermore, this population may be
more primed to generate mature cell
types for regenerative medicine
applications.REFERENCES
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Individual tumors harbor heterogeneous populations of genetically distinct subclones. Two recent papers in
Nature by Notta et al. (2011) and Anderson et al. (2011) reveal genetic heterogeneity in functional leukemic
stem cells, which has important implications for how both cancer and normal stem cell populations may
adapt to selective pressure.Cancer cell population heterogeneity
exists at many levels: for example, pheno-
typic, functional, genetic, and epigenetic.
Understanding the nature of this hetero-
geneity, how it arises, and how different
aspects of heterogeneity impact on each
other are important not only in furthering
knowledge of tumor biology but also in
improving clinical outcomes for cancer
patients.
From a Darwinian perspective, clonal
genetic heterogeneity provides a sub-strate for clonal evolution, disease pro-
gression, or relapse. The original clonal
evolution hypothesis suggested there
was a sequential, ‘‘linear’’ acquisition of
collaborating mutations in a tumor popu-
lation (Nowell, 1976). More recently,
deep sequencing of clonal markers and
analysis of copy number alterations sug-
gest that tumor subclones might be orga-
nized in nonlinear, branching clonal fami-
lies (Campbell et al., 2010; Mullighan
et al., 2008).In parallel lines of enquiry, many groups
have shown that cancer populations
may contain functionally heterogeneous
populations. For example, initial work
from the Dick laboratory in adult acute
myeloid leukemia (AML), and then later
from other laboratories in different
tumors, showed that only a rare sub-
set of largely quiescent, long-lived
cells with self-renewal capacity, termed
cancer stem cells (CSCs), sustain disease
and replenish differentiated downstream
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Previewsnon-self-renewing progeny when serially
transplanted into immunodeficient mice.
The CSC hypothesis does not presup-
pose the cell of origin of the cancer (cell
within which initiating tumorigenic change
occurred), which may be a stem cell
or progenitor (reviewed in Reya et al.,
2001).
Since these original observations were
made, there has beenmuch debate about
the hierarchical structure of tumors, the
rarity of CSC and their relationship to
normal stem cells. For example, in AML
distinct immunophenotypic and molec-
ular classes of engrafting cell populations
have been identified that molecularly are
more closely related to normal progeni-
tors (Goardon et al., 2011). Childhood
acute lymphoblastic leukemia (ALL) may
not be hierarchically ordered, and ALL
leukemia stem cells (LSCs) are not as
rare as in AML (1/100 cells in ALL versus
1/104–1/106 in AML) (Goardon et al.,
2011; le Viseur et al., 2008). Similarly, in
melanoma, as many as 1/4 cells have
tumor propagating properties, though
this may be true only for aggressive meta-
static melanoma (Boiko et al., 2010; Quin-
tana et al., 2008). Finally, some leukemia-
propagating populations may not
recreate the whole hierarchy of the tumor,
but initiate/propagate the tumor in a xeno-
graft and are, therefore, sometimes
referred to as leukemia initiating or propa-
gating cells (LIC).
There are probably multiple technical,
but also conceptual, explanations for
these discrepant observations. The
higher frequency readout of LSC in ALL
than AML may reflect more efficient
lymphoid, compared to myeloid, engraft-
ment in current immunodeficient mouse
strains. Conceptually, differences in
tumor cell hierarchies may reflect differ-
ences in normal cellular hierarchies
between different tissues. A shallower
normal hierarchy may allow more tumor
cells to exhibit tumor-propagating poten-
tial. If normal cells can re-enter the stem
cell compartment from an early progen-
itor compartment, this capacity may
allow phenotypic switching in the tumor.
Morever, the hierarchical structure of
cancer clones most likely changes as
tumorigenesis proceeds. Thus, one may
expect variations in cell hierarchies and
CSC frequencies between diseases,
between individual patients, and within
the same patient in response to therapyor at disease progression. Notwith-
standing these issues, the central
concept that tumors contain functionally
distinct cell populations is important
when dissecting cellular and molecular
relationships in tumor populations and
their closest normal cellular counterparts
and in our attempts to deliver effective
antitumor therapy that prevents tumor
recurrence.
Two papers that have appeared
recently in Nature from the Dick/Downing
(Notta et al., 2011) and Greaves/Enver
(Anderson et al., 2011) laboratories look
more closely in two cytogenetically
distinct groups of ALLs. Together, they
provide complementary and new insights
into the cellular and hierarchical basis for
the genetic heterogeneity in LICs. The
Dick/Downing study uses global SNP
arrays, and the Greaves/Enver groups
perform multiplex fluorescence in situ
hybridization to determine subclonal
diversity in patient samples and engrafted
tumors in xenografts. Though the two
techniques used to visualize subclonal
diversity both have limitations, together
they provide similar persuasive
conclusions.
Initial patient samples contain a variable
number of genetically distinct subclones.
By interrogating single leukemic cells for
possible combinations of a number of
genetic events, the Anderson paper, in
particular, confirms the complex, branch-
ing nature of clonal relationships in tumor
cell populations reminiscent of the Dar-
win’s diagram of speciation. Importantly,
the data argue that recurrent, presumed
driver, copy-number alterations are not
acquired in any preferential order and
can be acquired independently on
multiple occasions, raising questions
about whether these loci are targeted for
DNA breakage. Furthermore, there are,
as anticipated, changes in subclonal
genetic diversity with disease state either
reflecting changing dominance of clones
with the disease process (preleukemic
phase compared to overt leukemia) or in
response to the selective pressure of
chemotherapy (presentation sample
compared to chemotherapy resistant
relapse sample).
Critically, both groups show that when
either bulk or flow-sorted populations, en-
riched for LIC, are transplanted into
immunodeficient mice, multiple geneti-
cally distinct LIC populations are present.Cell Stem CeBoth papers convincingly show that in
some cases the composition of clonal
mix in the patient is accurately reflected
in the xenograft (i.e., concordant) whereas
in other cases, this is not true (i.e., non-
concordant). There is a suggestion from
Notta et al. that patients have a poorer
outcome in the cases where there is
concordance compared to nonconcord-
ance. Intuitively, this pattern suggests
that genetic alterations that lead to clonal
dominance and competitive advantage in
a xenograft also give rise to chemo-
therapy resistance.
Where do these findings take us now?
Genetic diversity of tumor propagating
populations is almost certain to extend
to all tumors. Furthermore, the findings re-
ported by Anderson et al. and Notta et al.
are only the initial snapshots of the likely
diversity. Not only do they underestimate
the extent of genetic diversity, but
tumor-propagating populations are likely
to also exhibit epigenetic diversity
(Sharma et al., 2010). A description of
the full extent of diversity will require
improvements in functional assays and
unbiased genetic and epigenetic analysis
in order to read out single cells. What are
the potential implications of these find-
ings? From a clinical perspective, it will
be important to track subclonal diversity
through therapy to understand if cancer
stem cells are the cellular reservoir
that causes relapse. Moreover, they
further emphasize the need, and chal-
lenge, to deploy therapeutic approaches
targeting disparate tumor propagating
populations.REFERENCES
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Researchers have long debated whether new pancreatic b cells derive from stem cells or from pre-existing
b cells. A new study in this issue of Cell Stem Cell (Smukler et al., 2011) suggests that both sides may be
right.The potential to cure type 1 diabetes
through b cell transplantation has stimu-
lated extensive research into the develop-
ment, homeostasis, and regeneration of
this cell type. For more than a century, a
particularly controversial question has
been whether new b cells arise via differ-
entiation from adult stem cells or by prolif-
eration of existing b cells. A study in this
issue offers a surprising answer: ‘‘yes’’
(Smukler et al., 2011).
Two studies from 2004 provide essen-
tial context for this work. First, Dor et al.
(2004) performed a pioneering lineage-
tracing experiment to address the origin
of adult b cells. Using a now paradigmatic
‘‘pulse-chase’’ approach, they heritably
labeled pre-existing mouse b cells with
a tamoxifen-inducible Cre transgene, rat
insulin promoter (RIP)-CreER, and asked
what happened to the fraction of labeled
cells over time or after injury. Despite an
overall increase in b cell numbers with
age or during regeneration, the labeling
index was found to remain approximately
constant, rather than progressively
declining because of a major influx from
unlabeled stem cells. They inferred that
b cell expansion was primarily driven by
the division of already differentiated cells,
a conclusion amplified by subsequent
confirmatory reports (Brennand et al.,
2007; Nir et al., 2007; Salpeter et al.,
2010; Teta et al., 2007).This work may have overshadowed
another paper published that same year
by the van der Kooy lab, from which the
current Smukler et al. paper originates,
suggesting that multipotent stem cells
do exist in the pancreas (Seaberg et al.,
2004). These authors applied the ‘‘neuro-
sphere’’ assay—dissociated cells, cul-
tured in suspension with high levels of
mitogens—to the adult mouse pancreas.
Multicellular clusters were found to arise,
clonally, from cultures of endocrine islets
at a low but reproducible rate (1/5,000
cells). More strikingly, transferring these
clusters to adherent, low-mitogen condi-
tions triggered differentiation into a sur-
prising array of endocrine, exocrine, and
neural cell types. Among these were
insulin+ cells, with marker expression
and glucose responsiveness similar to
b cells (Seaberg et al., 2004). Despite
these findings, the rarity of pancreas-
derived multipotent precursor (PMP) cells
and their surprising multipotency left
several questions. From which cell type
of the adult pancreas, if any, did PMPs
arise? Could PMPs produce enough
functional b cells to make a difference to
diabetes? And did cells with similar differ-
entiation properties exist in vivo? The
current study at least partially answers
these questions (Smukler et al., 2011).
With respect to origins, the authors
have now excluded a nonpancreaticorigin for PMPs, ruling out contamination
by neural crest or other known adult
stem cells. Extending their findings, the
authors used a GFP transgene under con-
trol of the mouse insulin promoter (MIP-
GFP mice) to separate insulin-expressing
and nonexpressing cells prior to culture.
Their very surprising finding was that
PMPs arose from cells expressing insulin,
but exhibiting a gene expression profile
closer to embryonic b cell precursors
(Smukler et al., 2011). The authors could
also derive PMPs from primary human
islets and these, like their mouse counter-
parts, could largely restore normoglyce-
mia when transplanted into diabetic
mice. From an applied science perspec-
tive, this remarkable result supports
pursuing the clinical utility of these rare
cells. Nonetheless, skeptics might con-
sider these advances incremental, given
the initial characterization of PMP cells
(Seaberg et al., 2004), and would certainly
want to knowwhether PMP-like cells exist
in vivo. Here, the evidence assembled by
Smukler and colleagues does leave room
for doubt.
The authors use the RIP-CreER trans-
gene (Dor et al., 2004) to label b cells
with GFP expression in adult mice and
then followed the expression of GFP
within the islets and beyond, either one
day after the end of tamoxifen treatment
(the ‘‘pulse’’) or 10 weeks thereafter (the
